BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 14683653)

  • 1. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.
    Geisbert TW; Hensley LE; Jahrling PB; Larsen T; Geisbert JB; Paragas J; Young HA; Fredeking TM; Rote WE; Vlasuk GP
    Lancet; 2003 Dec; 362(9400):1953-8. PubMed ID: 14683653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees.
    Moons AH; Peters RJ; Cate Ht; Bauer KA; Vlasuk GP; Büller HR; Levi M
    Thromb Haemost; 2002 Oct; 88(4):627-31. PubMed ID: 12362234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia.
    de Pont AC; Moons AH; de Jonge E; Meijers JC; Vlasuk GP; Rote WE; Büller HR; van der Poll T; Levi M
    J Thromb Haemost; 2004 Jan; 2(1):65-70. PubMed ID: 14717968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X.
    Vlasuk GP; Bradbury A; Lopez-Kinninger L; Colón S; Bergum PW; Maki S; Rote WE
    Thromb Haemost; 2003 Nov; 90(5):803-12. PubMed ID: 14597974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2.
    Geisbert TW; Daddario-DiCaprio KM; Geisbert JB; Young HA; Formenty P; Fritz EA; Larsen T; Hensley LE
    J Infect Dis; 2007 Nov; 196 Suppl 2(Suppl 2):S372-81. PubMed ID: 17940973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor/factor VIIa pathway mediates coagulation activation in induced-heat stroke in the baboon.
    Bouchama A; Al-Mohanna F; Assad L; Baturcam E; Eldali A; Owaidah T; Dehbi M
    Crit Care Med; 2012 Apr; 40(4):1229-36. PubMed ID: 22080642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice.
    Weijer S; Schoenmakers SH; Florquin S; Levi M; Vlasuk GP; Rote WE; Reitsma PH; Spek CA; van der Poll T
    J Infect Dis; 2004 Jun; 189(12):2308-17. PubMed ID: 15181580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.
    Hensley LE; Stevens EL; Yan SB; Geisbert JB; Macias WL; Larsen T; Daddario-DiCaprio KM; Cassell GH; Jahrling PB; Geisbert TW
    J Infect Dis; 2007 Nov; 196 Suppl 2():S390-9. PubMed ID: 17940975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant.
    Vlasuk GP; Rote WE
    Trends Cardiovasc Med; 2002 Nov; 12(8):325-31. PubMed ID: 12536118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor.
    Lee AY; Vlasuk GP
    J Intern Med; 2003 Oct; 254(4):313-21. PubMed ID: 12974870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endotoxaemia induces resistance to activated protein C in healthy humans.
    de Pont AC; Bakhtiari K; Hutten BA; de Jonge E; Vlasuk GP; Rote WE; Levi M; Büller HR; Meijers JC
    Br J Haematol; 2006 Jul; 134(2):213-9. PubMed ID: 16846480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty.
    Moons AH; Peters RJ; Bijsterveld NR; Piek JJ; Prins MH; Vlasuk GP; Rote WE; Büller HR
    J Am Coll Cardiol; 2003 Jun; 41(12):2147-53. PubMed ID: 12821239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
    Hembrough TA; Swartz GM; Papathanassiu A; Vlasuk GP; Rote WE; Green SJ; Pribluda VS
    Cancer Res; 2003 Jun; 63(11):2997-3000. PubMed ID: 12782609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever.
    Bray M; Geisbert TW
    Int J Biochem Cell Biol; 2005 Aug; 37(8):1560-6. PubMed ID: 15896665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
    Rijneveld AW; Weijer S; Bresser P; Florquin S; Vlasuk GP; Rote WE; Spek CA; Reitsma PH; van der Zee JS; Levi M; van der Poll T
    Crit Care Med; 2006 Jun; 34(6):1725-30. PubMed ID: 16625114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.
    Geisbert TW; Young HA; Jahrling PB; Davis KJ; Kagan E; Hensley LE
    J Infect Dis; 2003 Dec; 188(11):1618-29. PubMed ID: 14639531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.
    Lee A; Agnelli G; Büller H; Ginsberg J; Heit J; Rote W; Vlasuk G; Costantini L; Julian J; Comp P; van Der Meer J; Piovella F; Raskob G; Gent M
    Circulation; 2001 Jul; 104(1):74-8. PubMed ID: 11435341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease.
    Nishimura H; Yamaya M
    Tohoku J Exp Med; 2015 Sep; 237(1):45-50. PubMed ID: 26346967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques.
    Twenhafel NA; Mattix ME; Johnson JC; Robinson CG; Pratt WD; Cashman KA; Wahl-Jensen V; Terry C; Olinger GG; Hensley LE; Honko AN
    Vet Pathol; 2013 May; 50(3):514-29. PubMed ID: 23262834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.